Matthew Mishan

“Are there any meaningful milestones for Propeller or the Verily joint venture (now Primasun) in FY '22 that you could call out, as the loss is a lower loss on the JV because it's now generating some revenue?”

“I assume the $12 floor doesn't include the Diabetes carve-out. Do you have a better sense of what dilution is from that and impact to operating margin on a pro forma basis?”

“The revenue growth of mid-single digits for FY 2022 excluding Alaris and testing, obviously testing is like the negative. But is Alaris a good guy or a bad guy for next year?”

“I listened to the HCA calls, which is a major hospital system in the U.S. They seem to be integrating hospice and home health into their systems. How can you work with large hospital systems as they migrate into the home to scale?”

“Hey, Mick, just a quick one for me, just what is the pushback from the payer community on closing the gap in reimbursement between at-home sleep testing and lab-based tests?”